2024
899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice
VIJAYAKUMAR A, SRODA N, MURAKAMI E, WENG S, MYERS R, SUBRAMANIAN M, SHULMAN G. 899-P: Combinations of the Mitochondrial Protonophore TLC-6740 and/or the ACC2 Inhibitor TLC-3595 Provide Additive Glycemic Benefits to Semaglutide (SEMA) in db/db Mice. Diabetes 2024, 73 DOI: 10.2337/db24-899-p.Peer-Reviewed Original ResearchOral glucose tolerance testGLP-1R agonistsDb/db miceIncremental AUCGlucose tolerance testMale db/db miceImproved glucose toleranceSemaglutide groupGlycemic parametersSemaglutideTolerance testFood intakeGlucose toleranceGLP-1RLiver-targeted mitochondrial uncouplerDb/dbMiceGlucose bolusVEHAgonistsEvaluation of combinationsHbA1cDiabetesMitochondrial uncouplingAssess effects
2018
Glycemic Variability from CGM Correlates with Indices of Glucose Metabolism in Healthy Obesity but Not in Type 2 Diabetes
ELSHAFIE A, LAM W, PARIKH L, RANGEL E, SCHMIDT C, HWANG J, YECKEL C, SHERWIN R, BELFORT-DEAGUIAR R. Glycemic Variability from CGM Correlates with Indices of Glucose Metabolism in Healthy Obesity but Not in Type 2 Diabetes. Diabetes 2018, 67 DOI: 10.2337/db18-82-lb.Peer-Reviewed Original ResearchGlucose infusion rateInsulin secretion-sensitivity index-2Beta-cell functionContinuous overlapping net glycemic actionGlucose variabilityContinuous glucose monitorT2D subjectsObese subjectsInsulin levelsGV indicesGlucose metabolismCell functionInsulin sensitivity indexType 2 diabetesGlycemic Risk AssessmentCGM indicesHealthy obesityMannKind CorporationHealthy obeseOB subjectsGlycemic excursionsInsulin resistanceIncremental AUCGlycemic variabilityRegeneron Pharmaceuticals
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply